Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. - Investor Relations & Filings

Listed IPO Dec 2018
Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 376 across all filing types
Latest filing 2026-07-16 Major Shareholding Noti…
Country KR South Korea
Listing KO 298380 · 1 venue

Key figures FY2025

Period ended 2025-12-31 · KRW
Headline annual figures for ABL Bio Inc., fiscal year 2025, reported in KRW, with the source filing for each figure.
Total Revenues KRW 79.35B per the Audit Report / Information filed 2026-03-12
Net Income KRW -36.60B per the Audit Report / Information filed 2026-03-12
Total Assets KRW 281.87B per the Audit Report / Information filed 2026-03-12
Total Equity KRW 157.78B per the Audit Report / Information filed 2026-03-12
Cash from Ops KRW -40.21B per the Audit Report / Information filed 2026-03-12

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Financial Investment Services and Capital Markets Act. It details the shareholding status, changes in shareholding, and collateral agreements (stock-backed loans) of a major shareholder (the CEO). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership levels and changes therein.
2026-07-16 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (이중항체 면역항암제 ABL503의 제1상 임상시험계획 (IND) 변경승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from ABL Bio regarding the approval of a clinical trial plan (IND) amendment by the FDA. It follows the standard format for 'Major Management Matters' (투자판단관련주요경영사항) in the Korean market, which is a type of regulatory filing used to inform shareholders of material business developments. Since it does not fit into specific categories like financial reports, earnings releases, or board changes, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous regulatory announcements.
2026-07-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and collateral agreements (stock-backed loans) of a major shareholder. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and related party interests.
2026-07-06 Korean
기업설명회(IR)개최
Investor Presentation Classification Held out of the broad gpt-era re-classification: filing ingested <48h ago, so a realtime re-analysis could re-fire a filing.processed webhook. Prior label kept. 2026-07-04.
2026-07-02 Korean
기업설명회(IR)개최
Investor Presentation Classification Held out of the broad gpt-era re-classification: filing ingested <48h ago, so a realtime re-analysis could re-fire a filing.processed webhook. Prior label kept. 2026-07-04.
2026-07-02 Korean
기업설명회(IR)개최
Investor Presentation Classification Held out of the broad gpt-era re-classification: filing ingested <48h ago, so a realtime re-analysis could re-fire a filing.processed webhook. Prior label kept. 2026-07-04.
2026-07-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.